AFEKTA TECHNOLOGIES LTD

Their core work

Afekta Technologies is a Finnish bioinformatics and multi-omics analytics SME specializing in the analysis of microbiome-host interactions using advanced genomic and systems biology methods. They apply metagenomics, metatranscriptomics, and metabolomics to decode complex biological systems — from the human gut to agricultural animal microbiomes. Their work sits at the interface of data science and biology: they turn raw omics data into interpretable biological insight. In practice, this means they contribute specialized analytical pipelines and computational expertise to research consortia rather than running wet-lab experiments themselves.

What they specialise in

How they've shifted over time

Afekta's early H2020 work (2018) centred on the human gut microbiome and its therapeutic potential — specifically engineering microbial communities to treat metabolic conditions like obesity, with strong emphasis on metabolomics and metatranscriptomics. Their more recent project (from 2021) marks a clear pivot toward food and agricultural systems, shifting the application domain from human health to animal husbandry, while simultaneously upgrading the methodological toolkit to include structural genomics and hologenomics. The underlying technical competency — multi-omics analysis of host-microbiota systems — is consistent across both phases, but the target domain has broadened from clinical to agri-food.

Afekta appears to be repositioning multi-omics expertise toward the food and agriculture value chain, making them increasingly relevant for consortia targeting sustainable food production, animal health, and microbiome-based quality improvement.

How they like to work

Afekta has participated in all projects as a non-coordinating partner, suggesting they join consortia as a specialist contributor rather than a project driver. With 28 unique partners across 13 countries spread over just two projects, their consortia tend to be large and internationally diverse — typical of RIA and MSCA-ITN networks. This profile points to an organization that brings a specific, hard-to-replace technical capability (omics analytics) to multi-partner projects rather than building their own collaborative networks from scratch.

Afekta has worked with 28 distinct consortium partners across 13 countries through just two projects, indicating dense, pan-European networks rather than bilateral partnerships. No repeated partner data is available, but the breadth suggests they are comfortable operating in large, geographically distributed consortia.

What sets them apart

Afekta occupies a rare niche as a private SME — not a university or institute — with deep multi-omics and microbiome analytics capabilities, operating at the intersection of human health and food systems. Most omics-focused SMEs specialize in either clinical diagnostics or agricultural biotech; Afekta has demonstrated credibility in both domains within H2020. For a consortium coordinator, they offer computational microbiome expertise with a commercial orientation, which is often harder to find than academic equivalents.

Highlights from their portfolio

• 3D-omics
  Their largest project by funding (EUR 901,875) and most ambitious scientifically — applying three-dimensional hologenomics to animal-product microbiota, bridging food science and cutting-edge genomics methodology.
• BestTreat
  Their entry into EU research via an MSCA-ITN training network, demonstrating early credibility in gut microbiome therapeutics and willingness to engage in researcher training alongside technical contribution.